TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday.

TGTX has been the topic of a number of other reports. ValuEngine cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, September 17th. B. Riley began coverage on shares of TG Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $10.00 price target on the stock. LADENBURG THALM/SH SH set a $27.00 price target on shares of TG Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 26th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of TG Therapeutics in a research report on Monday, November 12th. Finally, Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Friday, November 16th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $14.95.

TGTX stock opened at $4.92 on Wednesday. The firm has a market capitalization of $407.86 million, a price-to-earnings ratio of -2.58 and a beta of 1.84. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.12. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. On average, equities research analysts anticipate that TG Therapeutics will post -2.03 EPS for the current fiscal year.

In other TG Therapeutics news, CFO Sean A. Power sold 37,275 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $4.13, for a total value of $153,945.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 15.10% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Claraphi Advisory Network LLC purchased a new position in TG Therapeutics in the 3rd quarter worth about $123,000. Belpointe Asset Management LLC purchased a new position in TG Therapeutics in the 3rd quarter worth about $243,000. MetLife Investment Advisors LLC increased its stake in TG Therapeutics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 43,884 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 15,600 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in TG Therapeutics in the 3rd quarter worth about $361,000. Finally, Alliancebernstein L.P. increased its stake in TG Therapeutics by 31.8% in the 3rd quarter. Alliancebernstein L.P. now owns 82,540 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 19,900 shares in the last quarter. 57.30% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Recommended Story: What are the benefits of a balanced fund?

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.